You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國醫療集團(08225.HK)參與研究藥物獲得批件
阿思達克 11-10 08:54
中國醫療集團(08225.HK)公佈,參與研究的邁可欣(中國唯一被批準的國產利託那韋口服液),而關聯企業萬全獲得批件。集團的收益通常爲研究服務CRO和科研商業推廣服務CRSO,因此集團將長期從產品銷售中獲益。 中療抗病毒臨牀研究中心與世界頂尖研究機構發現從抗擊SARS病毒開始,一批抗愛滋病藥物就可以發揮積極作用。其中利託那韋(Ritonavir)是人免疫缺陷病毒-1(HIV-1)和人免疫缺病毒-2(HIV-2)天冬氨酸蛋白(酉每)抑制劑。新冠病毒與HIV病毒同屬於冠狀病毒,利託那韋可能通過相同機制發揮作用。據報道,在本次聯合使用中,小劑量的利託那韋與PF-07321332合用可以減緩PF-07321332在體內的代謝/分解,以使其在體內保持較高的濃度來對抗病毒。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account